Leukocyte Growth Factor [EPC] class drugs

21 results

  • granix - tbo - filgrastim injection, solution

    (Tbo-Filgrastim)
    Cephalon, Llc
    Granix reduces the duration of severe neutropenia in adults and pediatric patients (1 month and older) with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant risk of febrile neutropenia.
    Medication Details
    Drug Interactions

  • leukine - sargramostim injection, powder, lyophilized, for solution

    (Sargramostim)
    Partner Therapeutics, Inc.
    Leukine is a leukocyte growth factor used to shorten neutrophil recovery after AML chemotherapy in adults 55+, mobilize stem cells for transplant, accelerate myeloid reconstitution after bone marrow or progenitor cell transplantation, treat delayed neutrophil recovery or graft failure, and increase survival after myelosuppressive radiation exposure.
    Medication Details
    Drug Interactions

  • neulasta - pegfilgrastim

    (Pegfilgrastim)
    Amgen, Inc
    Neulasta reduces infection risk from febrile neutropenia in adults and pediatric patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy. Also increases survival in patients acutely exposed to myelosuppressive radiation doses. Not indicated for stem cell transplantation progenitor cell mobilization.
    Medication Details
    Drug Interactions

  • neupogen - filgrastim injection, solution

    (Filgrastim)
    Amgen, Inc
    NEUPOGEN is a leukocyte growth factor used to reduce infection risk and neutropenia in cancer patients on chemotherapy or bone marrow transplant, treat AML-related neutropenia, mobilize stem cells for collection, manage severe chronic neutropenia, and improve survival after myelosuppressive radiation exposure.
    Medication Details
    Drug Interactions

  • nivestym - filgrastim - aafi injection, solution

    (Filgrastim-Aafi)
    Pfizer Laboratories Div Pfizer Inc
    Nivestym is a leukocyte growth factor indicated to reduce febrile neutropenia in nonmyeloid malignancy patients on myelosuppressive chemotherapy, shorten neutrophil recovery in AML, reduce neutropenia after bone marrow transplantation, mobilize progenitor cells for leukapheresis, and treat severe chronic neutropenia (congenital, cyclic, or idiopathic).
    Medication Details
    Savings Programs
    1
    Drug Interactions